NASDAQ:CGEM - Cullinan Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $51.75
  • Forecasted Upside: 103.42 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$25.44
▼ -0.81 (-3.09%)
1 month | 3 months | 12 months
Get New Cullinan Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CGEM and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CGEM

Average Price Target: $51.75
▲ +103.42% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Cullinan Oncology in the last 3 months. The average price target is $51.75, with a high forecast of $55.00 and a low forecast of $43.00. The average price target represents a 103.42% upside from the last price of $25.44.

Buy

The current consensus among 4 investment analysts is to buy stock in Cullinan Oncology.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/7/2021Morgan StanleyBoost Price TargetOverweight$40.00 ➝ $43.00High
6/4/2021HC WainwrightBoost Price TargetBuy$48.00 ➝ $55.00Medium
6/4/2021SVB LeerinkBoost Price TargetOutperform$48.00 ➝ $54.00High
4/27/2021Morgan StanleyUpgradeEqual Weight ➝ OverweightHigh
4/26/2021Morgan StanleyBoost Price TargetEqual Weight ➝ Overweight$38.00 ➝ $40.00N/A
4/19/2021Morgan StanleyBoost Price TargetEqual Weight$38.00 ➝ $40.00Medium
3/30/2021HC WainwrightBoost Price TargetBuy$47.00 ➝ $48.00Low
2/2/2021Morgan StanleyInitiated CoverageEqual Weight$38.00Low
2/2/2021Evercore ISIInitiated CoverageOutperform$55.00Low
2/2/2021SVB LeerinkInitiated CoverageOutperform$52.00N/A
2/1/2021HC WainwrightInitiated CoverageBuy$47.00Low
(Data available from 6/21/2016 forward)
Cullinan Oncology logo
Cullinan Management, Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Management, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $25.44
Low: $24.80
High: $26.60

50 Day Range

MA: $30.80
Low: $25.44
High: $35.91

52 Week Range

Now: $25.44
Low: $24.80
High: $59.85

Volume

1,071,100 shs

Average Volume

269,759 shs

Market Capitalization

$1.11 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cullinan Oncology?

The following Wall Street sell-side analysts have issued reports on Cullinan Oncology in the last year: Evercore ISI, HC Wainwright, Morgan Stanley, and SVB Leerink LLC.
View the latest analyst ratings for CGEM.

What is the current price target for Cullinan Oncology?

4 Wall Street analysts have set twelve-month price targets for Cullinan Oncology in the last year. Their average twelve-month price target is $51.75, suggesting a possible upside of 103.4%. Evercore ISI has the highest price target set, predicting CGEM will reach $55.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $43.00 for Cullinan Oncology in the next year.
View the latest price targets for CGEM.

What is the current consensus analyst rating for Cullinan Oncology?

Cullinan Oncology currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CGEM will outperform the market and that investors should add to their positions of Cullinan Oncology.
View the latest ratings for CGEM.

What other companies compete with Cullinan Oncology?

How do I contact Cullinan Oncology's investor relations team?

The company's listed phone number is 617-410-4650 and its investor relations email address is [email protected] The official website for Cullinan Oncology is www.cullinanoncology.com.